Essen

• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa … Recruiting
  2024-511392-15-00 5 2025-11-20 HR+/HER2- advanced breast cancer
• A study to find out whether BI 765423 has an effect on lung function in people with idiopathic pulmonary fibrosis (IPF) with or without stan … Recruiting
  2025-520658-12-00 4 2025-11-20 Idiopathic Pulmonary Fibrosis (IPF)
• adIVO Recruiting
  2024-520219-42-00 10 2025-11-18 ivosidenib maintenance after SOC adjuvant chemotherapy in curative mID
• Silexan® in mild to moderate major depressive disorder Recruiting
  2025-521744-37-00 5 2025-11-17 Mild to moderate major depressive disorder
• A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting
  2024-512849-17-00 5 2025-11-14 Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thromb … Recruiting
  2024-514401-54-00 5 2025-11-13 Chronic Primary Immune Thrombocytopenia
• Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting
  2024-515979-35-00 5 2025-11-13 Generalized Myasthenia Gravis
• Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced … Recruiting
  2024-519871-24-00 10 2025-11-11 Breast cancer
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
• A Study to Compare Vusolimogene oderparepvec (VO) Plus Nivolumab With the Doctor's Choice of Treatment in People With Skin Cancer That has G … Recruiting
  2023-508612-29-00 5 2025-11-07 Advanced Melanoma
• A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer. Recruiting
  2024-519654-37-00 10 2025-11-07 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
• Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting
  2025-521260-35-00 6 2025-11-07 acute ischemic stroke and atrial fibrillation (AF)
• A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant … Recruiting
  2024-516794-70-00 4 2025-11-03 Metastatic non-squamous non-small cell lung cancer
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici … Recruiting
  2024-519929-38-00 4 2025-10-27 Metastatic Colorectal Cancer without liver metastases
• A Phase 1/2 Study to Assess AMG 732 in Healthy Subjects and Subjects with Thyroid Eye Disease Recruiting
  2024-514110-12-00 7 2025-10-22 Thyroid Eye Disease
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid … Recruiting
  2025-520564-17-00 5 2025-10-16 Hidradenitis suppurativa (HS)
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06 Relapsing multiple sclerosis
• Long-term follow-up of patients treated with GD2IL18CART Recruiting
  2025-521497-34-00 1 2025-10-06 Neuroblastoma
• A study to investigate the efficacy and safety of rilzabrutinib in adult participants with Graves’ disease Recruiting
  2025-521023-75-00 4 2025-10-03 Immune system diseases

Showing 217–240 of 965 trials